Analyst Price Target is $13.17
▲ +76.97% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Fulcrum Therapeutics in the last 3 months. The average price target is $13.17, with a high forecast of $17.00 and a low forecast of $6.00. The average price target represents a 76.97% upside from the last price of $7.44.
Current Consensus is
Moderate Buy
The current consensus among 6 contributing investment analysts is to moderate buy stock in Fulcrum Therapeutics. This Moderate Buy consensus rating has held steady for over two years.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
